User:Mr. Ibrahem/Velmanase alfa

Velmanase alfa, sold under the brand name Lamzede, is a medication used to treat alpha-mannosidosis. Specifically it is used for non-central nervous system symptoms in mild to moderate disease. It is given by injection into a vein. Antihistamines and corticosteroids may be given before a dose.

Side effects are generally minimal. These may include allergic reactions, including anaphylaxis, fever, headache, joint pain, and weight gain. Use in pregnancy may harm the baby. It is a recombinant lysosomal human alpha-mannosidase and works by replacing the missing enzyme.

Velmanase alfa was approved for medical use in Europe in 2018 and the United States in 2023. It was the first replacement therapy for alpha-mannosidosis. In the United Kingdom it costs the NHS about £887 for 10 mg as of 2022.